Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Kidney Neoplasms 2Wilms Tumor 1Testicular Neoplasms 1Teratoma 1Sarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Liver Neoplasms 1Familial ependymoma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 3Everolimus 3atezolizumab 2Nivolumab 2Fluorodeoxyglucose F18 2FAPI-46 2tivozanib 1romidepsin 1pembrolizumab 1pasireotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1exemestane 1entrectinib 1cabozantinib 1alectinib 1Specimen Handling 1Respiratory Therapy 1Quality of Life 1Patient Reported Outcome Measures 1PT-100 dipeptide 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Lenalidomide 1Lactones 1LY2584702 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × PT-100 dipeptide × Genitourinary × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡